Professor Moghimi  co-chairs the 12th International Conference on Nanomedicine, Drug Delivery, and Tissue Engineering (NDDTE 2027). The conference which will take place in London, UK will cover key topics in nanomedicine, targeted drug delivery, tissue engineering, nanobiotechnology, nanopharmaceuticals, biomedical nanotechnology, cancer nanotechnology, gene delivery systems, nanotechnology for diagnosis and imaging, and related areas.

In a Nature Index editorial by Bec Crew, she outlines that the field of nanotechnology and nanomedicine seems to be on the cusp of big advances, but a concerted effort is needed to realize its true potential.  She further highlights an invited opinion article by Professor Moein Moghimi and CEO of S. M. Discovery Group (SMDG) Dr. Shadi Farhangrazi, published in the same issue and the importance of funding and support for development of novel therapies for pediatric patients with rare diseases.

“Good products are born of good science, and good science takes time, patience, and vision.”

On April 4, 2025, Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, spoke to Moein Moghimi, Professor of Pharmaceutics and Nanomedicine, Newcastle University and Adjoint Professor, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, about the evolution of conjugates to overcome lipid nanoparticle limitations. This article is based on that interview.

Professor Moghimi is a discussion leader at the The 3rd Mechanisms and Barriers in Nanomedicine Conference which will take place from September 10–12, 2026, at Golden Hotel in Golden, Colorado.

Webinar Insight:  Thought Leadership webinar on Unlocking the Brain – Innovations in CNS Drug Discovery and Neurodegenerative Treatment. This one-hour webinar captures an exclusive interview with Dr. Emma Mead, Chief Scientific Officer at Alzheimer’s Research UK, and a lively panel discussion with Professor Moein Moghimi of Newcastle University and University of Colorado, Dr. Shadi Farhangrazi of SMDG Discovery Group, and Dr. Ralph Minter of Alchemab – examining new technologies, translational approaches, and therapeutic opportunities while addressing challenges.

Professor Moghimi speaks about “Targeting complement attack on nanoparticle surfaces" at the 17th PharmSci International Conference,taking place from September 7th to 9th, 2026, at the Hilton Newcastle Gateshead Hotel in the UK.

Event Insight:  SMDG is invited to present about its pioneering and innovative platforms at the Venture Capital Unit (VCU) Health Tech Showcase. The event will be attended by global investors and companies. The companies give short pitches, and  will describe their innovative solutions and groundbreaking advancements in AI-driven health tech, engineering biology and medical technologies. Each company is raising capital to fund growth and international expansion.